Plus   Neg

Exact Sciences Sees Higher Revenue In Q4

Exact Sciences Corp. (EXAS) announced that it expects to report revenue between $142.5 million and $143.5 million for the fourth quarter ended December 31, 2018, an increase of 64 percent from the same quarter of 2017. The company completed approximately 292,000 Cologuard tests during the fourth quarter of 2018, which represents 66-percent growth from the same period of 2017.

For full-year 2018, the company anticipates reporting total revenue between $454 million and $455 million, a year-over-year increase of 71 percent. Completed Cologuard test volume during 2018 was approximately 934,000 tests, a 64-percent increase from 2017.

Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018. The number of providers who have ordered Cologuard since its launch increased to nearly 147,000 during 2018.

Exact Sciences plans to report 2018 financial results and provide guidance during its February 2019 earnings call.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT